

CERTIFICATE

Survey of 12 July 2024

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Tumor Markers (292):

Validity 6 months:

CA 15-3 (R: B1a)

CEA (R: B1a)

PSA, total (R: B1a)

alpha-1-Fetoprotein (R: B1a)

hCG intact +beta-hCG (R: B1a)

Validity 12 months:

CA 125

CA 19-9

PSA, free

SCC

(R) analysis is subject to the RiliBÄK

Customer:

10020781


Zakład Diagnostyki Laboratoryjnej

Mazowieckiego Szpitala Onkologicznego

Kościelna 61

05-135 Wieliszew

Düsseldorf, 17 September 2024



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Stefan Holdenrieder
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 12 July 2024

You have participated in the External Quality Assessment with the following analysis

Tumor Markers (292):

CA 125
CA 15-3 (R: B1a)
CA 19-9
CEA (R: B1a)
PSA, free
PSA, total (R: B1a)
SCC
alpha-1-Fetoprotein (R: B1a)
hCG intact +beta-hCG (R: B1a)

(R) analysis is subject to the RiliBÄK

Customer:
10020781
Zakład Diagnostyki Laboratoryjnej
Mazowieckiego Szpitala Onkologicznego
Kościelna 61
05-135 Wieliszew

Düsseldorf, 17 September 2024



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Stefan Holdenrieder
(Adviser)